Article Details
Retrieved on: 2024-06-21 16:45:56
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Tremfya was the first FDA-approved, fully-human, dual-acting monoclonal antibody to block interleukin (IL)-23—a significant driver of the ...
Article found on: www.appliedclinicaltrialsonline.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here